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Abstract 
Primary immunodeficiencies are inherited disorders of the immune system, often caused by the 
mutation of genes required for lymphocyte development and activation. Recently, several studies 
have identified gain-of-function mutations in the phosphoinositide 3-kinase (PI3K) genes PIK3CD 
(which encodes Ɖ ? ? ?ɷ ?ĂŶĚPIK3R1 (which encodes Ɖ ? ?ɲ ?ƚŚĂƚĐĂƵƐĞĂĐŽŵďŝŶĞĚŝŵŵƵŶŽĚĞĨŝĐŝĞŶĐǇ
syndrome, referred to as activated PI3Kį syndrome (APDS) or p110G-activating mutation causing 
senescent T cells, lymphadenopathy and immunodeficiency (PASLI). Paradoxically, both loss-of-
function and gain-of-function mutations that affect these genes lead to immunosuppression, albeit 
via different mechanisms. Here, we ƌĞǀŝĞǁ ƚŚĞ ƌŽůĞƐ ŽĨ W/ ?<ɷ ŝŶadaptive immunity, describe the 
ĐůŝŶŝĐĂů ŵĂŶŝĨĞƐƚĂƚŝŽŶƐ ĂŶĚ ŵĞĐŚĂŶŝƐŵƐ ŽĨ ĚŝƐĞĂƐĞ ŝŶ W^ ĂŶĚ ŚŝŐŚůŝŐŚƚ ŶĞǁ ŝŶƐŝŐŚƚƐ ŝŶƚŽ W/ ?<ɷ
gleaned from these patients, as well as implications of these findings for clinical therapy. 
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Introduction 
ĐƚŝǀĂƚĞĚ W/ ?<ɷsyndrome  (APDS; also known as PASLI) is among a growing number of newly 
defined primary immunodeficiency (PID)  syndromes in which the causal mutations have been 
identified by next-generation sequencing. The clinical manifestations of APDS are diverse and 
heterogeneous (Box 1), but the majority of patients present with recurrent respiratory infections, 
often associated with airway scarring (bronchiectasis) and ear and sinus damage, which is suggestive 
of antibody (B cell) deficiency. Severe, recurrent or persistent infections with herpes family viruses, 
indicating defective T cell function, are also common in this condition, and may cause early death in 
some affected individuals. Many patients develop benign lymphadenopathy, often associated with 
hepatosplenomegaly, and there is a substantially increased risk of B cell lymphoma associated with 
APDS (Box 1). Increased susceptibility to viral infection and poor recall responses of memory T cells 
differentiate APDS from isolated hypogammaglobulinemia  1-4, hence APDS should be considered a 
combined immunodeficiency5. More than 100 patients have been reported to date with APDS, but 
the precise incidence is not yet known6, 7. 
APDS is caused by heterozygous gain-of-function (GOF) mutations in PIK3CD or PIK3R1 that induce 
hyperactivation of the protein products Ɖ ? ? ?ɷŽƌƉ ? ?ɲ ?ƌĞƐƉĞĐƚŝǀĞůǇ1-4. dŚĞƉ ? ?ɲƌĞŐƵůĂƚŽƌǇƐƵďƵŶŝƚ
ĂŶĚƉ ? ? ?ɷĐĂƚĂůǇƚŝĐƐƵďƵŶŝƚƚŽŐĞƚŚĞƌĨŽƌŵƚŚĞŚĞƚĞƌŽĚŝŵĞƌŝĐůŝƉŝĚŬŝŶĂƐĞW/ ?<ɷ ?ǁŚŝĐŚŝƐĞŶŐĂŐĞĚďǇ
multiple receptors in cells of the immune system, including the B cell receptor (BCR) and the T cell 
receptor (TCR), as well as cytokine and costimulatory receptors. Homozygous loss-of-function (LOF) 
mutations in these same subunits cause a distinct and much rarer form of immunodeficiency in 
humans, which can be re-capitulated in mice8-10, and this apparent dichotomy, together with the 
clinical features of the affected patient groups, ŚĂƐŝŶĨŽƌŵĞĚŽƵƌƵŶĚĞƌƐƚĂŶĚŝŶŐŽĨƚŚĞƌŽůĞŽĨW/ ?<ɷ
in immune cell development and function. 
/ŶƚŚŝƐƌĞǀŝĞǁ ?ǁĞǁŝůůƐƵŵŵĂƌŝƐĞǁŚĂƚŝƐŬŶŽǁŶĂďŽƵƚW/ ?<ɷ ?ĨŽĐƵƐŝŶŐŽŶŝƚƐƌĞŐƵůĂƚŝŽŶŽĨĂĚĂƉƚŝǀĞ
immune responses. Much of this knowledge derives from studies using gene-targeted mice. We will 
then summarise the two cases that ŚĂǀĞ ďĞĞŶ ƌĞƉŽƌƚĞĚ ŽŶ W/ ?<ɷ-deficiency in humans, before 
describing in greater detail the clinical and immunological manifestations of APDS.  
Overview of class I PI3Ks  
The class IA PI3Ks are heterodimeric proteins composed of (and named after) a Ɖ ? ? ?ɲ ? Ɖ ? ? ?ɴ Žƌ
Ɖ ? ? ?ɷĐĂƚĂůǇƚŝĐƐƵďƵŶŝƚ that constitutively associates with a p85 regulatory subunit; the sole class IB 
PI3K is composed of the Ɖ ? ? ?ɶ catalytic subunit that interacts with a p101 or p84 regulatory subunit 
(Table 1). p ? ? ?ɲ ĂŶĚ Ɖ ? ? ?ɴ ĂƌĞ ďƌŽĂĚůǇ ĞǆƉressed, ǁŚĞƌĞĂƐ Ɖ ? ? ?ɶ ĂŶĚ Ɖ ? ? ?ɷare predominantly 
expressed by leukocytes. Although there is substantial potential for redundancy among the catalytic 
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subunits, unique roles for each individual p110 isoform have been described, reflecting their 
different expression patterns as well as how they are engaged by their respective receptors8, 11. For 
ĞǆĂŵƉůĞ ? Ɖ ? ? ?ɲis activated by insulin-like receptors and regulates growth, metabolism and 
angiogenesis11, whereas p ? ? ?ɴĐŽŶƚƌŝďƵƚĞs to metabolic signalling and has been shown to regulate 
responses of mouse neutrophils to immune complexes  12, 13 ?W ? ? ?ɶ ŝƐŚŝŐŚůǇĞǆƉƌĞƐƐĞĚ ŝŶŵyeloid 
cells and contributes to chemotactic responses, as well as reactive oxygen species (ROS) production 
in neutrophils14 ?dŽŐĞƚŚĞƌǁŝƚŚƉ ? ? ?ɷ ?Ɖ ? ? ?ɶŝƐĂůƐŽŝŵƉŽƌƚĂŶƚĚƵƌŝŶŐƉĞ-T cell development in the 
thymus15. p ? ? ?ɷ, which is the focus of this review, is highly expressed both in lymphocytes and 
myeloid cells and is activated by antigen receptors, costimulatory receptors, cytokine receptors and 
growth factor receptors8. 
Class I PI3Ks catalyse the phosphorylation of PtdIns(4,5)P2 to generate PtdIns(3,4,5)P3 (PIP3), which 
acts as a membrane tether for cell signalling proteins with pleckstrin homology (PH) domains. 
Prominent among these are PDK1 and AKT, which act in concert to phosphorylate substrates such as 
the FOXO transcription factors (which become inactivated) and regulators of the mTOR complex 1 
(which becomes activated). Therefore, activation of class I PI3Ks results in inactivation of FOXO 
transcription factors. In lymphocytes, BTK and ITK are PIP3-responsive tyrosine kinases that 
contribute to the activation of phospholipase C-ŐĂŵŵĂ  ?W>ɶ ? ĂŶĚ ŽƚŚĞƌ ĚŽǁŶƐƚƌĞĂŵ ƐŝŐŶĂůůŝŶŐ
proteins (Figs 1, 2). The lipid phosphatase PTEN converts PIP3 back to PtdIns(4,5)P2 8.  
Class IA PI3K regulatory subunits are encoded by three different genes (PIK3R1, PIK3R2 and PIK3R3) 
(Table 1). PIK3R1 ĞŶĐŽĚĞƐƉ ? ?ɲ ?Ɖ ? ?ɲĂŶĚƉ ? ?ɲ ?ĞĂĐŚĨƌŽŵan alternative transcription start site), 
PIK3R2 encodes p85E, and PIK3R3 ĞŶĐŽĚĞƐ Ɖ ? ?ɶ 16. These regulatory subunits have SH2 domains, 
which bind phosphorylated YXXM motifs of cell surface receptors and membrane-associated 
proteins. Ɖ ? ?ɲ ?Ɖ ? ?ɲ ?Ɖ ? ?ɲĂŶĚƉ ? ?ɴĂƌĞubiquitously ĞǆƉƌĞƐƐĞĚ ?ǁŚĞƌĞĂƐƉ ? ?ɶŝƐŵĂŝŶůǇĞǆƉƌĞƐƐĞĚ
in the brain and testes 16. ŶǇŽĨƚŚĞĐůĂƐƐ/W/ ?<ƌĞŐƵůĂƚŽƌǇƐƵďƵŶŝƚƐĐĂŶďŝŶĚƚŽƉ ? ? ?ɲ ?Ɖ ? ? ?ɴand 
Ɖ ? ? ?ɷ ǁŝƚŚŽƵƚ ĂƉƉĂƌĞŶƚ ƐĞůĞĐƚŝǀŝƚǇ ? W/ ?<ɷ ŝƐ ďĞƐƚ ƵŶĚĞƌƐƚŽŽĚ ƚŽ ĐŽŵƉƌŝƐĞ Ɖ ? ?ɲ ǁŝƚŚ Ɖ ? ? ?ɷ  ďƵƚ
ĂƐƐŽĐŝĂƚŝŽŶďĞƚǁĞĞŶƉ ? ? ?ɷand any of the other class IA PI3K regulatory subunits is also possible. It 
ŝƐĂůƐŽŝŵƉŽƌƚĂŶƚƚŽƌĞĐŽŐŶŝƐĞƚŚĂƚƉ ? ?ɲŚĂƐŵĂŶǇƉ ? ? ?ɷ-independent functions, as it can also bind 
Ɖ ? ? ?ɲĂŶĚƉ ? ? ?ɴ 16. 
 The class IA PI3K regulatory subunits influence the p110 catalytic subunits in three ways17: they 
prevent proteolytic degradation of p110; they inhibit p110 catalytic activity; and they recruit the 
p110 subunit to tyrosine phosphorylated proteins at the plasma membrane.  
Once the SH2 domains ŽĨƉ ? ?ɲare engaged by phosphotyrosines, the inhibitory contacts with p110 
are relieved17. Thus, mutations in the PIK3R1 gene can influence PI3K activity by allowing the 
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degradation of p110į or by diminishing its recruitment to receptors (in the case of PIK3R1 null or 
LOF mutations), or by releasing the inhibitory action of p85Į on p110į (in the case of PIK3R1 GOF 
ŵƵƚĂƚŝŽŶƐ ? ?/ŶĂĚĚŝƚŝŽŶƚŽƚŚĞƌĞŐƵůĂƚŽƌǇƐƵďƵŶŝƚƐ ?Ɖ ? ? ?ɲĂŶĚƉ ? ? ?ɷĐĂŶďŝŶĚRAS and Ɖ ? ? ?ɴďŝŶĚƐ
RAC or CDC42. These small GTPases help tether the p110 subunit to the membrane once it has been 
recruited to a receptor via its regulatory subunit17, 18.  
W/ ?<ɷand immunity: lessons from mice  
Prior to the description of APDS, most of our knowledge of ƚŚĞ ƌŽůĞ ŽĨ W/ ?<ɷ ŝŶ ŝŵŵƵŶŝƚǇ ĂŶĚ
infection was based on genetic and pharmacological studies using mouse models. The GOF 
mutations that cause APDS have recently been shown to result in increased basal and stimulated 
PIP3 levels and PIP3-dependent signalling cascades in patient-derived lymphocytes1-4, and the study 
of these patients may give us new insights into how the balance of PI3Kį activity regulates immune 
cell functions. Here, we summarise what these studies in mice have taught us, before describing the 
immunological phenotypes of human patients with mutations in PIK3R1 or PIK3CD. 
Loss of W/ ?<ɷfunction in mouse B cells  
In mice, early B cell development in the bone marrow is only ŵŝůĚůǇĂĨĨĞĐƚĞĚďǇƚŚĞůŽƐƐŽĨƉ ? ?ɲŽƌ
Ɖ ? ? ?ɷ19-23, whereas the ĐŽŵďŝŶĞĚůŽƐƐŽĨƉ ? ? ?ɲĂŶĚƉ ? ? ?ɷůĞĂĚƐƚŽĂŶĞĂƌ-complete development 
block at the pro-B cell stage24. However, mŝĐĞůĂĐŬŝŶŐƚŚĞƉ ? ?ɲŽƌƉ ? ? ?ɷƐƵďƵŶŝƚƐŚĂǀĞfewer 
follicular B cells, lack marginal zone (MZ) B cells and peritoneal B1 B cells, have reduced serum 
immunoglobulins, and respond poorly to vaccination19-23 ?W/ ?<ɷĐŽƵƉůĞƐZĂĐƚŝvation with both 
PIP3 production and signalling events downstream of the BCR (Fig 1) ?W/ ?<ɷ-deficient B cells fail to 
respond to mitogenic stimuli, but undergo class-switch recombination (CSR)  in response to 
interleukin-4 (IL-4) and lipopolysaccharide (LPS) in vitro19-26. However, miĐĞůĂĐŬŝŶŐƉ ? ? ?ɷƐĞůĞĐƚŝǀĞůǇ
in B cells can produce high-affinity IgG antibodies in response to immunisation with the T cell-
dependent (TD) antigen NP-CGG27 (but as discussed later, germline loss of PIK3R1 or PIK3CD leads to 
attenuated TD antibody responses). By contrast, W/ ?<ɷactivity within B cells is required for T cell-
independent (TI) antibody responses . This may be due in part to the loss of B1 and MZ B cell 
subsets, which are the dominant B cell subsets that respond to TI antigens, ŝŶW/ ?<ɷ-deficient mice21, 
22, 27, 28. 
Consequences ŽĨŚǇƉĞƌĂĐƚŝǀĞW/ ?<ɷƐŝŐŶĂůůŝŶŐŝŶĐĞůůƐŝŶŵŝĐĞ 
While there are several mouse models of LOF mutations in Pik3cd, the phenotype of Pik3cd GOF-
mutant mice remains to be described. We can however, make inferences from other models of 
hyperactive PI3K signalling (in which Pten or Foxo1 is ablated in the germline or in B cells) or from 
mice expressing a membrane-bound form ŽĨƉ ? ? ?ɲŝŶĐĞůůƐ. PTEN antagonises PI3K signalling and 
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hence its ablation leads to elevated PIP3 levels. FOXO transcription factors are negatively regulated 
by PI3K-AKT, and hence, their loss mimics some of the effects of hyperactive PI3K-AKT signalling. 
FOXO transcription factors induce the expression of genes involved in immunoglobulin gene 
recombination and development such as Rag1, Rag2, Ikaros and Il7a (Fig 1)29-31. Failure to undergo 
VDJ recombination because of elevated PI3K signalling and subsequent inactivation of FOXO1 can 
lead to a partial block of B cell development in the bone marrow29, 30. In addition, elevated PI3K 
signalling can increase the sensitivity of developing Pten-null B cells to negative selection by self 
antigens32. Interference with RAG expression and/or negative selection may lead to the 
development of B cells with aberrant phenotypes, as observed in patients with APDS (see later). 
Activation-induced cytidine deaminase  (AID; encoded by Aicda) is the master regulator of CSR and 
somatic hypermutation  (SHM) 33. Deletion of Pten or Foxo1 in B cells impairs immunoglobulin class 
switching26, 30, 34, 35, suggesting that increased PI3K signalling in B cells antagonise this process. 
Indeed, adĚŝƚŝŽŶŽĨĂW/ ?<ɷŝŶŚŝďŝƚŽƌĐĂŶƌĞƐƚŽƌĞ^Zin Pten-/- cells in vitro 35. AID is induced by 
FOXO1 and in-vitro activated Foxo1ʹ/ʹ B cells (which mimic B cells with GOF PI3Kį mutations) exhibit 
impaired CSR, due partially to the loss of Aicda transcription; however, inefficient CSR was still 
observed in Ptenʹ/ʹ B cells in the presence of ectopic AID, suggesting that PI3K signalling also 
regulates CSR by affecting AID function at the post-transcriptional level26, 34, 35. During the germinal 
centre reaction , B cells cycle between the light zone and dark zone. B cells interact with cognate T 
cells in the light zone, and if they receive the appropriate signals, undergo CSR and then traffic to the 
dark zone where they proliferate and undergo SHM36. When, Foxo1 was deleted specifically in 
germinal centre B cells, CSR was impaired despite normal Aicda transcription and AID protein 
expression. This suggests that FOXO1 regulates the targeting of AID to the immunoglobulin gene 
locus, that FOXO1 targets other genetic loci required for CSR and SHM, and/or that Foxo1 deletion in 
germinal centre B cells affects the expression of other proteins required for CSR37, 38. Moreover, 
Foxo1 ablation or induction of PI3K  activity in germinal centre B cells led to loss of germinal centre 
dark zones due to aberrant trafficking of B cells, at least in part as a consequence of lost expression 
of CXC-chemokine receptor 4 (Cxcr4), which is a target of FOXO137, 38. Hence, failure to expand 
antigen-specific B cells that have undergone selection in the germinal centre light zone is an 
additional cause of impaired high affinity class-switched antibody production.  
Together, these findings contrast the effects of impaired PI3K signalling versus unrestrained PI3K 
signalling in B cells: W/ ?<ɷĚĞĨŝĐŝĞŶĐǇŝŶŵĂƚƵƌĞĐĞůůƐŝŵƉĂŝƌƐTI antibody responses but does not 
affect CSR or SHM27, whereas, hyperactivation of PI3K signalling in mature B cells interferes with CSR 
and SHM and promotes the expansion of antigen-specific B cell populations in the germinal centre 
dark zones (Fig 2) 26, 34, 35. 
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W/ ?<ɷŝƐƌĞƋƵŝƌĞĚĨŽƌŵŽƵƐĞ ?+ T cell differentiation and Treg cell function 
/ĨW/ ?<ɷ-deficient B cells can undergo CSR, then why ĚŽW/ ?<ɷ-deficient mice fail to respond to T cell-
dependent vaccines? The answer relates to the provision of T cell help for B cell development and 
immunoglobulin class switching. ICOS is a T cell costimulatory receptor and a potent activator of 
W/ ?<ɷ ?Mutant mice in which ICOS has been uncoupled ĨƌŽŵW/ ?<ɷ lack follicular helper T (Tfh) cells  
39 ? ^ŝŵŝůĂƌůǇ ? ĚĞůĞƚŝŽŶ ŽĨ ƚŚĞ Ɖ ? ? ?ɷ ƐƵďƵŶŝƚ ŝŶd ĐĞůůƐ ŝŶƚĞƌĨĞƌĞƐǁŝƚŚ ƚŚĞ ĚĞǀĞůŽƉŵĞŶƚ of Tfh cells, 
leading to a dramatic attenuation of T cell-dependent immune responses, including the induction of 
CSR and SHM in B cells27. These results highlight Ă ĚƵĂů ƌŽůĞ ĨŽƌ W/ ?<ɷ ŝŶ ĂŶƚŝďŽĚǇ ƉƌŽĚƵĐƚŝŽŶ P
inactivation of P/ ?<ɷ in B cells, which leads to activation of FOXO transcription factors, is a 
prerequisite for CSR and SHM26, 34, 35, ǁŚĞƌĞĂƐƚŚĞĂĐƚŝǀĂƚŝŽŶŽĨW/ ?<ɷŝŶdĨŚcells is a prerequisite for 
the provision of help to supports CSR and SHM in B cells27.  
Naïve CD4+ T cell differentiation towards the Th1, Th2 and Th17 cell lineages is delayed or 
ĂƚƚĞŶƵĂƚĞĚǁŚĞŶW/ ?<ɷŝƐŝŶŚŝďŝƚĞĚ40-42. This may reflect a key role for FOXO transcription factors in 
the suppression of Th cell differentiation, for example by suppressing the Ifng gene43, as well as the 
requirement for mTOR activity to promote Th cell differentiation44. A reduction in Th2 cell responses 
ƵŶĚĞƌƉŝŶƐƚŚĞƌĞƐŝƐƚĂŶĐĞŽĨW/ ?<ɷ-deficient mice to experimentally induced asthma, despite elevated 
IgE levels25, 45. In addition, reduced Th17 cell ƌĞƐƉŽŶƐĞƐ ŵĂǇ ƉƌŽƚĞĐƚ W/ ?<ɷ-deficient mice from 
experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis46. Although 
W/ ?<ɷ-deficient mice only develop a partial Th1 cell response to Leishmania major infections, W/ ?<ɷ-
deficient mice control Leishmania major infections more effectively than wild-type mice, likely due 
to defects in a regulatory immune cell population47.  
W/ ?<ɷis required for FOXP3+ regulatory T (Treg) cell homeostasis and function48 ? W/ ?<ɷ-deficient 
mice develop colitis because of inappropriate activation of effector T cells by gut microbes, and 
W/ ?<ɷ-deficient Treg fail to suppress experimental colitis22, 48. WĂƚŝĞŶƚƐ ƚĂŬŝŶŐ ƚŚĞ W/ ?<ɷ ŝŶŚŝďŝƚŽƌ
idelalisib (Zydelig; Gilead) also develop colitis, probably in part as a result of reduced Treg cell 
function49, 50. However, W/ ?<ɷ-ĚĞĨŝĐĞŶƚŵŝĐĞĂŶĚŵŝĐĞůĂĐŬŝŶŐƉ ? ? ?ɷŽŶůǇŝŶdƌĞŐcells mount a more 
effective immune response against a broad range of tumours than wild-type mice51. As with 
ĂŶƚŝďŽĚǇ ƉƌŽĚƵĐƚŝŽŶ ? ƚŚĞƐĞ ĚĂƚĂ ŚŝŐŚůŝŐŚƚ ƚŚĞ ĚƵĂů ŶĂƚƵƌĞ ŽĨ W/ ?<ɷ, which is required both for 
optimal cytokine production by effector T cells and for effective Treg cell-mediated tolerance. 
tŚĞƚŚĞƌ W/ ?<ɷ ŝŶŚŝďŝƚŝŽŶ ƌĞƐƵůƚƐ in impaired or enhanced cell-mediated immune responses is 
context dependent and therefore difficult to predict (Fig 3). Interestingly, inactivation of W/ ?<ɷ
results in the hyperresponsiveness of dendritic cells and macrophages to Toll-like receptor ligands, 
resulting in increased IL-12 production, which may further contribute to increased cell-mediated 
ŝŵŵƵŶĞƌĞƐƉŽŶƐĞƐƵƉŽŶ>K&ŽĨW/ ?<ɷ52.  
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W/ ?<ɷƌĞŐƵůĂƚĞƐŵŽƵƐĞ ?+ T cell effector functions 
W/ ?<ɷ-deficient CD8+ T cells stimulated in vitro are characterised by a reduced abundance of mRNAs 
encoding proteins associated with inflammation and cytotoxicity, such as /&Eɶ, granzyme B and 
perforin51, 53, 54. By contrast, the expression of genes regulating the homing of T cells to the lymph 
nodes, such as Sell (which encodes CD62L), Ccr7 and Klf2 are ŝŶĐƌĞĂƐĞĚŝŶW/ ?<ɷ-deficient CD8+ T cells 
stimulated in vitro55. Thus, W/ ?<ɷcan regulate the homeostatic trafficking of T cells to the lymph 
nodes and contributes to the reprogramming of CD8+ T cells to acquire full effector functions and 
migrate to peripheral tissues. 
W/ ?<ɷŝƐƌĞƋƵŝƌĞĚto reach the optimal magnitude of CD8+ T cell responses in vivo53, 56. Nevertheless, 
W/ ?<ɷ-deficient CD8+ dĐĞůůƐĐĂŶďĞĐŽŵĞĨƵůůǇĚŝĨĨĞƌĞŶƚŝĂƚĞĚĐǇƚŽƚŽǆŝĐdĐĞůůƐƚŚĂƚƉƌŽĚƵĐĞ/&EɶĂŶĚ
GZMB required for the killing of virus-infected cells or tumours; this suggests that the transcriptional 
defects described in vitro can, at least in part, be overcome by strong inflammatory stimuli in vivo51, 
53. Moreover, long-term CD8+ T ceůůŵĞŵŽƌǇ ƌĞƐƉŽŶƐĞƐĂƌĞ ŝŶƚĂĐƚ ŝŶW/ ?<ɷ-deficient mice53. This is 
partially because the generation of CD8+ effector T cells is reduced during recall responses, whereas 
the generation of long-term memory CD8+ T cells in the lymph nodes and bone marrow is 
preserved53. Similarly, the inhibition of the downstream kinase mTOR with low-dose rapamycin 
during vaccination or infection augments the generation of memory CD8+ T cells at the expense of 
effector CD8+ T cells57. Hence, by promoting mTOR activity, W/ ?<ɷƐŬĞǁƐ ?+ T cell differentiation in 
favour of effector T cells, but antagonises the generation of memory CD8+ T cells. Thus ?ƐƚƌŽŶŐW/ ?<ɷ
activity is associated with effector CD8+ T cell differentiation, whereas the maintenance of CD8+ T 
cell memory requires the suppression of PI3K signalling (Fig 4). 
Consequences of hyperactive PI3K signalling in mouse T cells 
Similar to B cells, tŚĞĐŽŶƐĞƋƵĞŶĐĞŽĨW/ ?<ɷŚǇƉĞƌĂĐƚŝǀĂƚŝŽŶŝŶŵŽƵƐĞdĐĞůůƐĐĂŶďĞŝŶĨĞƌƌĞĚĨƌŽŵ
experiments using PTEN-deficient or FOXO1-deficient T cells. Loss of PTEN expression in early T cell 
development leads to the development of an immature T cell lymphoma and a hyperactivated T cell 
phenotype, characterised by the increased secretion of effector T cell cytokines and autoimmunity58. 
Similar results were observed in mice expressing a mutant Ɖ ? ?ɲprotein that lacked inhibitory 
contacts with the p110 catalytic subunit59. Deleting PTEN in mature CD4+ T cells also resulted in 
enhanced cytokine production and Th cell function, but did not induce T cell transformation or 
autommunity60. Furthermore, loss of Foxo1 leads to a loss of memory CD8+ T cell development after 
infection61. Together, these data indicate a unique sensitivity of thymocytes ƚŽW/ ?<ɷ-dependent T 
cell transformation, and suggest that W/ ?<ɷƐŝŐŶĂůůŝŶŐĂůƐŽaffects central tolerance to self-peptides. 
Overall, these studies suggest that unrestrained PI3K signalling in T cells lowers their threshold of 
activation. 
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ůƚĞƌĂƚŝŽŶƐŝŶW/ ?<ɷƐŝŐŶĂůůŝŶŐůĞĂĚƐƚŽW/ƐŝŶŚƵŵĂŶƐ 
Both LOF and GOF mutations in PI3K genes that cause PIDs in humans have been described. Our 
understanding of the underpinning causes of these PIDs has been greatly aided by the use of mouse 
models (as described in the previous section), but have also furthered and challenged our 
understanding of the functions of W/ ?<ɷ (Box 2 and below). 
>ŽƐƐŽĨĨƵŶĐƚŝŽŶŽĨƉ ? ?ɲŽƌƉ ? ? ?ɷŝŶŚƵŵĂŶƐ 
Ɛ ǁŝƚŚ ŵŽƵƐĞ d ĐĞůůƐ ? ŝŶŚŝďŝƚŝŽŶ ŽĨ W/ ?<ɷ ŝŶ ŚƵŵĂŶ dĐĞůůƐ ƐƵƉƉƌĞƐƐĞs the expression of effector 
ĐǇƚŽŬŝŶĞƐƐƵĐŚĂƐ /&Eɶ ? />-4 and IL-17 41. A single patient with a homozygous PIK3R1 mutation that 
generated a premature ƐƚŽƉĐŽĚŽŶ ?ƌĞƐƵůƚŝŶŐŝŶƚŚĞůŽƐƐŽĨƉ ? ?ɲĂŶĚŵĂƌŬĞĚůǇĚĞĐƌĞĂƐĞĚĞǆƉƌĞƐƐŝŽŶ
ŽĨƉ ? ? ?ɷ ?ƉƌĞƐĞŶƚĞĚǁŝƚŚrecurrent pneumonia associated with agammaglobulinemia and severe B 
cell lymphopenia due to a block in early B cell development10. The development of colitis in this 
patient was attributed to antibody-deficiency and the consequent outgrowth of gut pathogens, but 
could also be due to Treg cell deficiency10 ? ^ŝŵŝůĂƌůǇ ? ŽŶĞ ƉĂƚŝĞŶƚ ůĂĐŬŝŶŐ Ɖ ? ? ?ɷ ĂƐ Ă ƌĞƐƵůƚ ŽĨ ƚŚĞ
inheritance of two different non-functional alleles has been described, and this patient presented 
with sinopulmonary infections, septic arthritis, inflammatory bowel disease and autoimmune 
hepatitis, associated with hypogammaglobulinemia9. Loss of p110G was again associated with severe 
B cell lymphopenia and fewer memory T cells9. Thus, the two reported patients with a loss of PI3KG 
suffer infections associated with the lack of B cells. Interestingly, in mice, a complete block in B cell 
development and severe mature B cell lymphopenia are ŽŶůǇŽďƐĞƌǀĞĚǁŚĞŶďŽƚŚƚŚĞƉ ? ? ?ɲĂŶĚ
Ɖ ? ? ?ɷ ĂƌĞ ŝŶĂĐƚŝǀĂƚĞĚ ŝŶ ƚŚĞ  ĐĞůů ůŝŶĞĂŐĞ24, suggesting a redundancy between these isoforms in 
mice that is not reflected in humans. The inflammatory and autoimmune manifestations ŝŶW/ ?<ɷ-
deficient humans, possibly associated with reduced Treg cell function, underscore the importance of 
PI3KG in maintaining self-tolerance. W/ ?<ɷ ŝƐ ĂůƐŽ ƌĞƋƵŝƌĞĚ ĨŽƌ ƚŚĞ ŐĞŶĞƌĂƚŝŽŶ ŽĨROS by human 
ŶĞƵƚƌŽƉŚŝůƐĂŶĚƚƌĞĂƚŵĞŶƚŽĨƉĂƚŝĞŶƚƐǁŝƚŚƚŚĞW/ ?<ɷŝŶŚŝďŝƚŽƌŝĚĞůĂůŝƐŝďĐĂŶůĞĂĚƚŽŶĞƵƚƌŽƉĞŶŝĂĂŶĚ
increased risk of infections 49, 62.  
ĐƚŝǀĂƚŝŶŐW/ ?<ɷŵƵƚĂƚŝŽŶƐƚŚĂƚƵŶĚĞƌůŝĞhuman APDS 
In 2013, groups in Cambridge (UK) and Bethesda (US) reported whole-exome sequencing studies of 
patients with uncharacterised PID, which revealed causal heterozygous activating mutations in 
PIK3CD1, 2. The UK patients were identified by screening cohorts of PID patients with a high 
frequency of recurrent chest infections and bronchiectasis, features suggestive of antibody 
deficiency, although frequent herpes viral infections and an increased proportion of effector T cells 
were also noted1. The US cohort were identified on the basis of persistent viremia with herpes-
family viruses, which are commonly associated with altered T cell or natural killer (NK) cell function, 
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in addition to frequent airway infections2. Because both B cells and T cells are affected in these 
patients, APDS should be characterised as a combined immunodeficiency1-5.  
This immunodeficiency had previously been noted in a Taiwanese boy by targeted sequencing of the 
PIK3CD gene in children with B cell immunodeficiency, although the nature of the mutation (GOF or 
LOF) was not elucidated63. Subsequently, a number of additional studies have identified APDS 
patients with mutations in PIK3CD5, 7, 64-69 or PIK3R16, 70-73. Patients with GOF mutations in either of 
these genes appear to largely phenocopy each other, despite the fact that p85Į is ubiquitously 
expressed and can pair with Ɖ ? ? ?ɲ ĂŶĚ Ɖ ? ? ?ɴ in addition to Ɖ ? ? ?ɷ. There is some evidence for 
effects of the PIK3R1 mutation outside the immune system (for example, short stature, Box 1)74, but 
detailed analyses of the effects ŽĨƚŚŝƐƉ ? ?ɲdefect on Ɖ ? ? ?ɲor Ɖ ? ? ?ɴhave not yet been reported. 
The biochemical and clinical symptoms of patients with APDS1 (PIK3CD mutations) or APDS2 (PIK3R1 
mutations) are similar, suggesting that the pathological features of both syndromes are a 
consequence of aberrant and hyperactive P/ ?<ɷ ƐŝŐŶĂůůŝŶŐ1-4. Here we use the generic term APDS 
unless referring specifically to either. A milder form of APDS-like immunodeficiency has been 
described in Cowden disease, caused by heterozygous loss of PTEN, although the increases in PIP3 
and pAKT levels from these patient T cells was less obvious than observed in the T cells from patients 
with APDS69, 75.  
The most frequent mutation in PIK3CD (c.3061G>A; OMIM 602839 
http://www.omim.org/entry/602839#0001) encodes a glutamic acid for lysine substitution at 
position 1021  ? ? ? ? ?< ? ŽĨ Ɖ ? ? ?ɷ (Table 1). To date, this mutation has only been found in APDS 
patients and their affected family members but not among healthy unrelated subjects1. Patients 
with the E1021K mutation have been found across continents and ethnicities. Genetic analysis 
showed no founder effect, demonstrating that E1021K is a recurrent mutation that appeared de 
novo independently in multiple unrelated families1. 
Ɖ ? ? ?ɷ with the E1021K mutation has increased lipid kinase activity, as shown using recombinant 
proteins in vitro and by measuring PIP3 and AKT phosphorylation levels in patient-derived T cells1, 2. 
The E1021K mutation is located in the C-terminal lobe of the kŝŶĂƐĞĚŽŵĂŝŶŽĨƉ ? ? ?ɷ ?ƐŝŵŝůĂƌůǇƚŽ
the oncogenic H1047R ŵƵƚĂƚŝŽŶ ŽĨ Ɖ ? ? ?ɲ, and enhances the membrane association of Ɖ ? ? ?ɷin 
vitro, facilitating more effective phosphorylation of its lipid substrate PtdIns(4,5)P2; this increases 
accumulation of PIP3 and lowers the activation threshold of W/ ?<ɷ1, 17 (Fig 3). Other missense Ɖ ? ? ?ɷ 
mutations  ?  N334K, C416R and E525K  ?  have also been shown to cause APDS, although they are 
less frequent than E1021K2 (Table 1). Interestingly, GOF mutations of the homologous amino acid 
residues of p110D (N345, C420 and E545, respectively), have been identified in tumors 
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(http://www.sanger.ac.uk/genetics/CGP/cosmic/) and are thought to interfere with the inhibitory 
contacts imposed by p85Į and hence increase the lipid kinase activity of the p110 subunit17; this 
implies that a similar mechanism may lead to enhanced PIP3 accumulation in cells from patients with 
APDS with the equivalent mutations and hence the immune modulation seen in APDS (Fig 4). APDS is 
thus distinct from most other PIDs in that it is the hyperactivation of signaling pathways, rather than 
their inhibition, that leads to immune dysfunction. This distinction offers unique therapeutic 
opportunities (see below). 
A heterozygous splice site mutation before exon 11 of the PIK3R1 gene leads to an in-frame fusion of 
exon 10 with exon 12, resulting in the deletion of 42 amino acids in p85D (del p.434  W 475, OMIM: 
http://omim.org/entry/616005) p55D and p50D3, 4(Fig 3). These amino acids lie in the inter-SH2 
domain that regulates the activity of the catalytic p110 subunits76. Oncogenic mutations in this 
region result in mutant proteins that can bind p110 subunits but are less effective at inhibiting their 
enzymatic activity76, 77. SimilĂƌ ƚŽ ŵƵƚĂƚŝŽŶƐ ŝŶ ƚŚĞ Ɖ ? ? ?ɷ ƐƵďƵŶŝƚ ? ƚŚŝƐ ŝƐ ƚŚŽƵŐŚƚ ƚŽ ůŽǁĞƌ ƚŚĞ
threshold of activation for W/ ?<ɷ. The mutant p85Ddel434 W475 protein (Fig 4 ? ȴǆ ? ? ? was shown to 
stabilize Ɖ ? ? ?ɷ, which was expressed at near normal levels in patient cells, but its inhibitory function 
was impaired, leading to increased W/ ?<ɷĂĐƚŝǀŝƚǇ3, 4. Because the net effect of the p85D (del p.434  W 
 ? ? ? ?ŝƐŝŶĐƌĞĂƐĞĚW/ ?<ɷĂĐƚŝǀŝƚǇ ?ǁĞĐŽŶƐŝĚĞƌŝƚĂƐĂ'K&ŵƵƚĂƚŝŽŶ ?ĞǀĞŶƚŚŽƵŐŚŝƚŝƐƐƚƌŝĐƚůǇƐƉĞĂŬŝŶŐ
a mutation resultin in loss of inhibitory function. 
Thus, a number of different mutations in PIK3R1 or PIK3CD lead to increased activity of PI3Kį, either 
ďǇĚŝƐƌƵƉƚŝŶŐŝŶŚŝďŝƚŽƌǇĐŽŶƚĂĐƚƐďĞƚǁĞĞŶƉ ? ?ɲĂŶĚƉ ? ? ?ɷŽƌ ďǇŝŶĐƌĞĂƐŝŶŐthe affinity of p110į for 
the plasma membrane, promoting its interaction with the lipid substrate and hence facilitating 
phosphorylation of PtdIns(4,5)P2.  
ĐƚŝǀĂƚŝŶŐW/ ?<ɷŵƵƚĂƚŝŽŶƐůĞĂĚƚŽimpaired B cell function and vaccine responses  
Immunoglobulin levels in patients with APDS are variable, ranging from isolated specific antibody 
deficiency or IgG subclass deficiency to severe hypogammaglobulinemia, often with increased IgM 
levels. In one cohort, 10% of a heterogeneous PID cohort who suffered recurrent infections were 
found to have APDS1, whereas in a second cohort of mainly antibody-deficient PID patients, fewer 
than 1% had PIK3CD mutations5.  
Most APDS patients have increased proportions of circulating transitional B cells , reduced class-
switched memory B cells, and impaired vaccine responses1,3. In vitro, APDS patient-derived B cells 
showed impaired CSR (consistent with the observed tendency for these patients to have reduced IgG 
and increased IgM levels), but in contrast to the findings in mouse cells, this was not associated with 
reduced AICDA mRNA levels2. As noted above, it is possible that PI3K regulates AID function by post-
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transcriptional mechanisms as well as by regulation of mRNA expression35. Alternatively, the 
defective CSR in APDS patients could be due to defects in germinal centre Tfh cells78, aberrant B cell 
maturation and/or defective migration of B cells during the germinal centre reaction in the spleen, 
as shown for FOXO1-deficient B cells in mice37, 38. The basis for the increased percentage of 
circulating transitional B cells in patients with APDS remains incompletely understood, but is likely to 
be a consequence of impaired B cell maturation and/or an increased propensity for mature B cells to 
undergo apoptosis1. These findings are in marked contrast to the dramatic loss of B cells and 
agammaglobulinemia seen in the rare patients with LOF mutations in PIK3R1 or PIK3CD.  
Encapsulated bacteria (Haemophilus influenzae and Streptococcus pneumoniae) are the most 
frequent respiratory isolates from patients with APDS (Box 1), which is consistent with a substantial 
defect in antibody-mediated immunity. However, the severity of respiratory infections and resulting 
structural damage in the lungs do not correlate well with the reduction in B cell numbers or the 
extent of immunoglobulin deficiency6, 7, and immunoglobulin replacement therapy alone does not 
appear to limit the progress of lung damage in patients with APDS 6, 7. One explanation for this 
apparent discrepancy is that W/ ?<ɷŚǇƉĞƌĂĐƚŝǀĂƚŝŽŶĐĂƵƐĞƐadditional defects (such as altered T cell 
functions or innate immune cell dysfunction) that also contribute to an increased susceptibility to 
respiratory bacterial infections. As mentioned above ? W/ ?<ɷ ŚĂƐ ďĞĞŶ ƐŚŽǁŶ ƚŽ ƉƌŽŵŽƚĞ ZK^
production by human neutrophils, which could cause collateral damage if excessively produced 
during infections62. However, analysis of APDS patient neutrophils did not reveal an obvious increase 
in ROS production, or indeed in PIP3 production, in response to stimulation with microbial peptides1. 
However, the increased susceptibility of patients with APDS to staphylococcal skin infections and 
abscess formation1, 65, as well as defective killing of mycobacteria by macrophages from an APDS 
patient64, suggest that abnormalities may indeed exist in the innate immune system which remain to 
be more completely investigated. Increased PI3K activity has been shown to compromise the 
migratory accuracy of neutrophils, and hence prolong their tissue-transit time, leading to increased 
opportunities for bystander tissue injury mediated by surface-associated neutrophil proteases79. 
Hence a wide range of impaired immune cell functions, affecting both innate and adaptive immune 
responses, may contribute to recurrent infection and bronchiectasis in patients with APDS. 
ĐƚŝǀĂƚŝŶŐW/ ?<ɷŵƵƚĂƚŝŽŶƐĐĂƵƐĞdĐĞůůƐĞŶĞƐĐĞŶĐĞ 
Peripheral blood analysis revealed an increase in effector-type T cells with a severe reduction in 
naïve T cell numbers1-4. Freshly isolated peripheral blood cells demonstrated reduced secretion of 
cytokines and increased apoptosis upon TCR restimulation1-3. Unexpectedly, acute W/ ?<ɷŝŶŚŝďŝƚŝŽŶin 
T cells from APDS patients reduced TCR-triggered apoptosis, suggesting a previously unappreciated 
role for W/ ?<ɷ ƐŝŐŶĂůůŝŶŐin pro-apoptotic pathways1, 3. However, T cell blasts that had escaped 
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apoptosis and expanded after activation in vitro showed increased production of IFNɶ ? TNF and 
granzyme B2. Thus, chronic hyperactivation of PI3Kį signalling promotes T cell differentiation into 
terminal effector cells with increased sensitivity to TCR-induced cell death and dysregulation of 
cytokine secretion.  
 
Notably, the expression of CD57, which is a marker of senescence  on CD8+ T cells 80, was 
consistently high on patient cells2, 4. Subsequent analyses confirmed shortening of telomere length in 
APDS patient lymphocytes4, suggesting T cell senescence contributes to immune dysfunction in APDS 
patients. Patients free from viraemia also presented with increased numbers of CD57+CD8+ T cells2; 
therefore, CD8+ T cell senescence in APDS is likely to be distinct from T cell exhaustion driven by 
chronic viral infections. T cell senescence due to telomere shortening results in cell cycle arrest while 
maintaining most other responses to antigen81, whereas T cell exhaustion from chronic antigen 
stimulation results in the upregulation of co-inhibitory receptors that broadly dampen TCR signalling 
and antigen responsiveness82. These findings point to in vivo hyperproliferation (which is consistent 
with enlarged spleen and lymph nodes) as the underlying cause of the T cell senescence and short 
telomeres in APDS patients and support the connection between cell division and effector T cell 
differentiation.  
 
T cells from APDS patients exhibit increased activity of mTOR2, a key mediator of the switch from a 
catabolic naïve state to an anabolic effector state during a T cell response83. Increased glucose 
uptake is also observed in T cells from APDS patients compared with healthy subjects2, 4. These 
findings indicate that changes in T cell metabolism induced by hyperactive PI3Kį signalling may 
underlie the hyperproliferation associated with T cell senescence in APDS patients. Further studies 
will be needed to determine if elevated mTOR activity is a direct consequence of increased PI3Kį 
activity or whether it also reflects the skewed effector phenotype of T cells in APDS patients. W/ ?<ɷ
inhibition reduced, but did not ablate, phosphorylation of S6K (a component of the mTOR signalling 
pathway) in APDS T cells, confirming ƚŚĂƚ W/ ?<ɷcontributes to mTOR activity in these cells4. 
Therefore, unrestrained and prolonged PI3Kį and mTOR activity may drive APDS T cells towards 
senescence rather than allowing T cells to revert to a metabolically quiescent phenotype after 
antigen exposure (Fig 3). 
 
The main clinical manifestation of abnormal T cell function in APDS is herpes viral infection. All of the 
patients with PIK3CD mutations that were described by Lucas et al.3 experienced chronic Epstein W
Barr virus (EBV) and/or cytomegalovirus (CMV) viremia; in other studies the occurrence of CMV/EBV 
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was lower1, 4-7, although herpes simplex virus and varicella zoster virus infections were also noted. 
These inter-study differences may reflect the case-finding strategies, immune profiles and/or 
pathogen exposure of the patients. Surprisingly, given the abnormal T cell profiles, few other 
opportunistic infections have been reported. Some cases of problematic viral warts and molluscum 
contagiosum have been identified7, perhaps suggesting impaired NK cell function, though this has 
yet to be confirmed experimentally.  
Treatment options for patients with APDS 
As APDS patients often present with reduced IgG levels or respond poorly to vaccines, many are 
treated with immunoglobulin replacement therapy that is often supplemented with prophylactic 
antibiotics. While this may have been effective in some patients, it has not prevented the acquisition 
or progression of bronchiectasis in others, even when the treatment was initiated in childhood6, 7. 
Haematopoietic stem cell transplantation (HSCT) is a treatment option, particularly for younger 
patients. HSCT could also help prevent or treat malignant B cell transformation, which occurs in 10 W
15% of patients. Several patients have undergone HSCT and, although significant improvements 
have been noted6, 7, the follow up of these patients is too short to make a definitive conclusion.  
Rapamycin 
Lucas and colleagues reported use of the mTOR inhibitor rapamycin in one patient, who showed a 
dramatic reduction in lymphadenopathy and hepatosplenomegaly and improvement in T cell subset 
defects2. Similar improvements have been noted in a recent case report of a four year old boy also 
treated with rapamycin68. However, the effect of rapamycin on B cell homeostasis and humoral 
immune responses in APDS patients remains to be determined. It is important to keep in mind that 
W/ ?<ɷ ƌĞŐƵůĂƚĞƐ ŽƚŚĞƌ ƉĂƚŚǁĂǇƐin addition mTOR, and conversely, that mTOR is also regulated 
byPI3K-independent pathways8. Moreover, mTOR regulates the expression of PTEN such that 
treatment of T cells with rapamycin can actually increase PI3K signalling in T cells84, potentially 
ĞǆĂĐĞƌďĂƚŝŶŐĂƐƉĞĐƚƐŽĨŚǇƉĞƌĂĐƚŝǀĞW/ ?<ɷƐŝŐŶĂůůŝŶŐŝŶAPDS. 
W/ ?<ɷŝŶŚŝďŝƚŽƌƐ 
The PI3Kɷ inhibitor idelalisib is licenced for use in chronic lymphocytic leukaemia and non-Hodgkin 
lymphoma85, 86. However, idelalisib has a considerable side-effect profile, including pneumonitis, 
pneumonia, transaminitis and colitis in up to 42% of patients treated49. Histologically, the colitis in 
these patients is reminiscent of that seen in mice lacking functional W/ ?<ɷ, suggesting it is an on-
target effect rather than a compound-specific effect49. It is possible that APDS patients will benefit 
ĨƌŽŵůŽǁĞƌĚŽƐĞƐŽĨW/ ?<ɷŝŶŚŝďŝƚŽƌƐ, which are effective for the treatment of B cell lymphomas, and 
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hence may be spared some of the more severe side effects. Another possibility is that topical 
ĂĚŵŝŶŝƐƚƌĂƚŝŽŶŽĨƚŚĞW/ ?<ɷŝŶŚŝďŝƚŽƌŵĂǇavoid some of the adverse effects.  
dǁŽ ĐůŝŶŝĐĂů ƚƌŝĂůƐ ŽĨ W/ ?<ɷ ŝŶŚŝďŝƚŽƌƐ ŝŶ patients with APDS have recently been announced: 
NCT02435173 ƐƉŽŶƐŽƌĞĚ ďǇ EŽǀĂƌƚŝƐ ĨŽƌ ĂŶ ŽƌĂů W/ ?<ɷ ŝŶŚŝďŝƚŽƌ ĂŶĚNCT02593539 sponsored by 
GlaxoSmithKline ĨŽƌ ĂŶ ŝŶŚĂůĞĚ W/ ?<ɷ ŝŶŚŝďŝƚŽƌ ? dŽ ĐŽƌƌĞĐƚ ƐǇƐƚĞŵŝĐ ŝŵŵƵŶĞ ĚĞĨĞĐƚs, including 
lymphoproliferation and lymphoma, an oral inhibitor is more likely to be effective; however, an 
inhaled inhibitor is expected to have a better safety profile and may be appropriate for patients who 
are primarily affected by airway infections and potentially may limit progression of bronchiectasis.  
Conclusions 
GOF mutations in PI3Kɷ ůĞĂĚƚŽĂƌĂŶŐĞŽĨB and T cell developmental and functional defects that 
compromise host defence, leading to recurrent bacterial and viral infections (Box 1). This 
ĚŝƐƚŝŶŐƵŝƐŚĞƐW^ƉĂƚŝĞŶƚƐĨƌŽŵƉĂƚŝĞŶƚƐǁŝƚŚ>K&ŽĨW/ ?<ɷǁŚŽƉƌĞƐĞŶƚǁŝƚŚŵƵĐŚŵŽƌĞƐĞǀĞƌĞ
cell lymphopenia and agammaglobulinemia, but not T cell senescence. In general, GOF mutations 
are unusual causes of immune deficiency87 ?dŚĞƚŚĞƌĂƉĞƵƚŝĐŽƉƚŝŽŶƐĨŽƌ>K&ŽĨW/ ?<ɷŵĂǇďĞůŝŵŝƚĞĚ
to immunoglobulin replacement therapy, bone marrow transplants and perhaps gene therapy. 
Although these are also options for APDS, existing (mTOR inhibitors) and emerging (PI3KɷŝŶŚŝďŝƚŽƌƐ ?
therapeutics offer the additional possibility of correcting the biochemical defects that arise from 
APDS-associated mutations, and the impact of these agents is currently being explored.  
The fact that both LOF and GOF W/ ?<ɷmutations lead to immunodeficiencies highlights the concept 
that this pathway must be precisely and dynamically modulated for optimal immune cell function: 
too much, too little or the inability to turn the pathway on or off as needed, has detrimental 
consequences (Fig 3) 8. These considerations raise the possibility that aberrant PI3K signalling in 
immune cells may also occur in non-genetic diseases or conditions that lead to increased 
susceptibility to infections.  
Many fundamental questions remain to be answered. How common is APDS among PID patients? 
What are some of the genetic or environmental influences that lead to the clinical heterogeneity of 
W^ƉĂƚŝĞŶƚƐ ?ƌĞƚŚĞƌĞŵƵƚĂƚŝŽŶƐŝŶŽƚŚĞƌŐĞŶĞƐƚŚĂƚůĞĂĚƚŽŚǇƉĞƌĂĐƚŝǀĂƚŝŽŶŽĨW/ ?<ɷĂŶĚW -^
like syndromes? Why do APDS T cells undergo apoptosis when stimulated? Why does recurrent 
airway infection lead to bronchiectasis more frequently in APDS patients than in other PIDs? Can 
W/ ?<ɷ ŝŶŚŝďŝƚŽƌƐ ƌĞƐƚŽƌĞ ŶŽƌŵĂů ŝŵŵƵŶĞ ĨƵŶĐƚŝŽŶ ŝŶ W^  ? dŚĞ ĂŶƐǁĞƌƐ ƚŽ ƚŚĞƐĞ ĂŶĚ ĨƵƌƚŚĞƌ
questions will require more detailed analysis of APDS patient cohorts, genetic screening of larger PID 
cohorts, and establishment of mouse models that mimic this intriguing new disease and help 
evaluate different therapeutic strategies. 
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Table 1. PI3K subunits and APDS mutations 
PI3K 
class 
Gene Protein Expression  Selected functions APDS-associated 
mutations** 
Catalytic subunits  
Class IA PIK3CA SĮ Ubiquitous x Metabolism 
x Angiogenesis 
ND 
PIK3CB Sȕ Ubiquitous x Metabolism 
x Neutrophil activation 
ND 
PIK3CD Sį Haematopoietic 
cells and CNS 
x Immunity  
Class IB PIK3CG SȖ Haematopoietic 
cells and heart 
 
x Immunity 
x Metabolism 
x Cardiac 
N334K (1) 2 
C416K (2) 65 
E525K (7) 2, E525A (3)69 
E1021K (63) 1, 2, 5, 7, 63-69 
Regulatory subunits  
Class IA PIK3R1 SĮ
SĮ
SĮ 
Ubiquitous x Metabolism  
x Immunity 
del p.434-475 (43) 3, 4, 6, 70-
74
 
PIK3R2 Sȕ Ubiquitous x Metabolism 
x Immunity 
ND 
PIK3R3 SȖ Brain and testes x Unknown ND 
Class IB PIK3R5 p101 Haematopoietic 
cells 
x Immunity ND 
 PIK3R6 p84*  Haematopoietic 
cells 
x Immunity ND 
*Also known as p87. ** Number of cases reported in brackets. ND, none described  
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Box 1. Clinical features of APDS 
Patients with APDS display features of both immune deficiency and of immune dysregulation: 
x Recurrent lung, ear and sinus infections (with encapsulated bacteria such as Haemophilus 
influenzae and Streptococcus pneumoniae, which require opsonisation for effective killing) 
are near-universal and are associated with a high incidence of organ damage including 
hearing impairment and bronchiectasis (permanent airway scaring)1-4. 
x Severe, recurrent or persistent infections with herpes family viruses are common, in 
particular chronic EBV or CMV viremia, and HSV and VZV infections1, 3-7. Frequent isolates of 
some respiratory viruses such as adenovirus and echovirus have also been described 1. 
x Opportunistic infections are rare, although a few patients have experienced recurrent viral 
warts or molluscum contagiosum infections49.  
x An increased incidence of abscess formation, lymphadenitis and cellulitis with gram-positive 
bacteria (mainly Staphylococcus aureus), and defective killing of mycobacteria by 
macrophages isolated from a patient with APDS suggest a mild deficit in innate immunity1, 64. 
x Benign lymphoproliferation (lymphadenopathy, hepatosplenomegaly and focal nodular 
lymphoid hyperplasia) is a common feature of all patients with APDS that have been studied 
to date.  
x Histopathological analysis of lymphoid tissue from affected patients demonstrates atypical 
follicular hyperplasia with attenuation of mantle zones in APDS1, and small B cell follicles in 
APDS2. Germinal centres were disrupted by infiltrating T cells (often PD1-positive) in both 
APDS1 and APDS2 6, 7. 
x There is a high frequency of lymphoma associated with APDS, encompassing a wide range of 
histopathological patterns1, 2, 7, 65, 67. 
x Immune cytopenias (thrombocytopenia, haemolytic anaemia and neutropenia) and 
autoimmune-like solid organ conditions (such as juvenile arthritis, glomerulonephritis, 
thyroiditis and sclerosing cholangitis) have also been reported7, 66, with a frequency of 34% in 
a cohort of 53 patients with APDS1 7 and 17% in a cohort of 36 patients with APDS2 6. 
x Mild developmental delays has been observed in both APDS1 and APDS2 cohorts, with a 
higher incidence in APDS2 (31% versus 19%) 6, 7. 
x Growth retardation is common in patients with APDS2 6, 73, 74 but does not seem to be a 
feature of APDS1 and may relate to the association of heterozygous mutations in PIK3R1 
with SHORT syndrome (short stature, hyperextensibility of joints, hernia, ocular depression, 
Rieger anomaly and teething delay)88-91. 
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Box 2: Lessons learned from APDS 
ůƚŚŽƵŐŚ ƚŚĞ ŶŽƌŵĂů ƉŚǇƐŝŽůŽŐŝĐĂů ƌŽůĞ ŽĨ W/ ?<ɷ ŚĂƐ ďĞĞŶ ĞǆƚĞŶƐŝǀĞůǇ ƐƚƵĚŝĞĚ ŝŶ ŵŽƵƐĞ ŵŽĚĞůƐ ?
investigation of patients with APDS has provided important new insights about the biology of this 
kinase in humans.  
x DƵƚĂƚŝŽŶƐĐĂƵƐŝŶŐ>K&Žƌ'K&ŽĨW/ ?<ɷůĞĂĚƚŽŝŵŵƵŶŽĚĞĨŝĐŝĞŶĐǇ ?dŚŝƐŝůůƵƐƚƌĂƚĞƐŚŽǁƚŚŝƐ
pathway needs to be dynamically regulated for normal immune cell function. 
x The pƌĞǀŝŽƵƐůǇ ƌĞƉŽƌƚĞĚ ƌŽůĞƐ ĨŽƌ W/ ?<ɷ ŝŶ  ĐĞůů ĨƵŶĐƚŝŽŶ ĂŶĚ ŚƵŵŽƌĂů ŝŵŵƵŶŝƚǇ ĚŝĚ ŶŽƚ
predict the increase of transitional B cell numbers that have been observed in APDS patients.  
x Defects in CSR that are not attributable to defective AICDA mRNA expression (encoding AID) 
remain to be fully understood.  
x Augmented PI3Kį results in a loss of naïve T cells and an in vivo proliferative burst that 
causes lymphoproliferative disease and drives the T cells toward cellular senescence (a 
phenotype that is poorly mimicked in mouse models due to long telomeres).  
x Moreover, patient T cells are highly susceptible to TCR restimulation-induced cell death, 
ŝŶĚŝĐĂƚŝŶŐĂƉƌĞǀŝŽƵƐůǇƵŶĂƉƉƌĞĐŝĂƚĞĚƌŽůĞĨŽƌW/ ?<ɷ in a pro-apoptotic signalling pathway.  
x The high proportion of patients with severe respiratory infections and bronchiectasis 
ƐƵŐŐĞƐƚƐ Ă ƌŽůĞ ĨŽƌW/ ?<ɷ ŝŶ ƉƌŽŵŽƚŝŶŐ ŝŶĨůĂŵŵĂƚŝŽŶ ŽĨ ƚŚĞ ůƵŶŐƐ ďǇŵĞĐŚĂŶŝƐŵƐ ƚŚĂƚ ĂƌĞ
ŝŶĐŽŵƉůĞƚĞůǇƵŶĚĞƌƐƚŽŽĚ ?ďƵƚǁŚŝĐŚŵĂǇŝŶĚŝĐĂƚĞĂŬĞǇƌŽůĞĨŽƌW/ ?<ɷ ŝŶĂŝƌǁĂǇ-associated 
innate immune responses, in addition to its role in humoral immunity. 
x Previously, LOF point mutations in PIK3R1 were shown to cause SHORT syndrome 88-91. It is 
unclear why the ȴǆ ? ?ŵƵƚĂƚŝŽŶƐƚŚĂƚĐĂƵƐĞW^ ?ŵĂŶŝĨĞƐƚƉƌŝŵĂƌŝůǇĂƐW/ ?ŚŽǁĞǀĞƌ ?ŝƚŝƐ
of interest to note at least one case where this mutation was suggested to relate to SHORT 
syndrome 73. This indicates that PIK3R1 ȴǆ ? ?ŵĂǇŚĂǀĞĚŝƐƚŝŶĐƚĞĨĨĞĐƚƐŽŶĚŝĨĨĞƌĞŶƚƉ ? ? ?
isoforms in different tissues.  
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Figure 1. BCR signaling 
W/ ?<ɷŝƐĂŚĞƚĞƌŽĚŝŵĞƌŝĐĞŶǌǇŵĞ ?ƚǇƉŝĐĂůůǇĐŽŵƉŽƐĞĚŽĨĂƉ ? ?ɲƌĞŐƵůĂƚŽƌǇƐƵďƵŶŝƚĂŶĚĂƉ ? ? ?ɷ
catalytic subunit. /ŶĐĞůůƐ ?W/ ?<ɷŝƐĂĐƚŝǀĂƚĞĚƵƉŽŶĐƌŽƐƐ-linking of the BCR, after stimulation with IL-
4 or by the chemokine CXCL13 via CXCR5. The BCR co-opts the co-receptor CD19 or the adapter 
ƉƌŽƚĞŝŶW ?ďŽƚŚŽĨǁŚŝĐŚŚĂǀĞzyyDŵŽƚŝĨƐƚŽǁŚŝĐŚƚŚĞƉ ? ?ɲ^, ?ĚŽŵĂŝŶƐĐĂŶďŝŶĚ ?dŚĞ/>-4R 
co-ŽƉƚƐ/Z^ ? ?ǁŚŝĐŚĂůƐŽŚĂƐzyyDŵŽƚŝĨƐ ?dŚĞŵĞĐŚĂŶŝƐŵǁŚĞƌĞďǇyZ ?ŝƐĐŽƵƉůĞĚƚŽW/ ?<ɷ
remains to be defined (indicated by a dotted line). PI3Kį signalling through AKT promotes the 
activation of mTOR and suppresses FOXO1 function (via phosphorylation-dependent nuclear export). 
FOXO1 is a transcription factor that activates the genes encoding RAG proteins involved in V(D)J 
recombination, IKAROS which is required for early B cell development, CD62L which is required for 
homing to lymph nodes and AID, which is required for CSR and SHM. The amino acid sensor mTOR 
contributes to the growth and proliferation of B cells. All proteins coloured in green have been 
ĂĨĨĞĐƚĞĚďǇ>K&ŵƵƚĂƚŝŽŶƐĐĂƵƐŝŶŐW/ ?KĨƚŚĞƐĞ ?ŽŶůǇƉ ? ?ɲĂŶĚƉ ? ? ?ɷŚĂǀĞĂůƐŽďĞĞŶĂĨĨĞĐƚĞĚďǇ
GOF mutations causing APDS.  
Figure 2. TCR signaling 
W/ ?<ɷŝƐĂŚĞƚĞƌŽĚŝŵĞƌŝĐĞŶǌǇŵĞ ?ƚǇƉŝĐĂůůǇĐŽŵƉŽƐĞĚŽĨĂƉ ? ?ɲƌĞŐƵůĂƚŽƌǇƐƵďƵŶŝƚĂŶĚĂƉ ? ? ?ɷ
catalytic subunit. In T cells, the TCR, the costimulatory receptor ICOS and the IL-2R can activate 
W/ ?<ɷ ?/K^ĐŽŶƚĂŝŶƐĂzyyDŵŽƚŝĨŝŶƚŚĞĐǇƚŽƉůĂƐŵŝĐĚŽŵĂŝŶǁŚŝĐh is essential for ICOS-mediated 
co-stimulation. Precisely how the TCR activates W/ ?<ɷƌĞŵĂŝŶƐŝŶĐŽŵƉůĞƚĞůǇƵŶĚĞƌƐƚŽŽĚ, though TCR 
ligation is known to induce ZAP70-mediated phosphorylation of LAT. Whether PI3K binds LAT 
directly or via other adapter proteins remains to be established. Mechanisms of PI3KG activation 
downstream of IL-2R are even less clear, but a role for JAK3 has been implicated. W/ ?<ɷĐŽŶƚƌŝďƵƚĞƐ
to the downregulation of the expression of IL-7RĮ and CD62L,via the AKT-dependent inactivation 
and nuclear export of FOXO1, preparing the T cell to exit the lymph nodes and circulate through the 
vascular systems and organs. W/ ?<ɷĂůƐŽincreases metabolism and contributes to T cell effector-
associated phenotypes by promoting activation of mTOR.  
&ŝŐƵƌĞ ? ?ǇŶĂŵŝĐƌĞŐƵůĂƚŝŽŶŽĨW/ ?<ɷƐŝŐŶĂůŝŶŐŝŶƚŚĞŝŵŵƵŶĞƐǇƐƚĞŵ 
W/ ?<ɷĂĐƚŝǀŝƚǇŶĞĞĚƐƚŽďĞĚǇŶĂŵŝĐĂůůǇƌĞŐƵůĂƚĞĚĨŽƌŶŽƌŵĂůŝŵŵƵŶĞĐĞůůĨƵŶĐƚŝŽŶ ?ĂƐƐŽŵĞĐĞůůƚǇƉĞƐ
ĂŶĚƉƌŽĐĞƐƐĞƐƌĞƋƵŝƌĞŚŝŐŚW/ ?<ɷĂĐƚŝǀŝƚǇ ?ǁŚŝůĞŽƚŚĞƌĚĞƉĞŶĚŽŶůŽǁW/ ?<ɷĂĐtivity (e.g., if they 
require FOXO1-dependent gene transcription). Problems arise if cells cannot increase or suppress 
W/ ?<ɷĚƵĞƚŽŵƵƚĂƚŝŽŶƐ ?ĂŶĚŚĂǀĞĐŚƌŽŶŝĐĂůůǇůŽǁŽƌŚŝŐŚW/ ?<įactivity. Immunosuppression is 
associated with loss-of function and gain-of-function in PIK3CD, which encoded the PI3Kį subunit 
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p110į ?/ůůƵƐƚƌĂƚĞĚĂƌĞƐŽŵĞŬĞǇĐĞůůƚǇƉĞƐĂŶĚƉƌŽĐĞƐƐĞƐĂĨĨĞĐƚĞĚďǇŚŝŐŚŽƌůŽǁW/ ?<ɷĂĐƚŝǀŝƚǇ ?ĂŶĚ
the consequences of being locked in one state or the other.  
In the healthy state (top), W/ ?<ɷsignalling is low in naïve and memory T cells, which are 
characterised by low mTOR and metabolic activity and high expression of FOXO1-dependent lymph 
ŶŽĚĞŚŽŵŝŶŐƌĞĐĞƉƚŽƌƐ ?/ŶĂĐƚŝǀĂƚĞĚĞĨĨĞĐƚŽƌdĐĞůůƐ ?W/ ?<ɷĂĐƚŝǀŝƚǇŝƐŚŝŐŚĂƐĂĐŽŶƐĞƋƵĞŶĐĞŽĨdZ ?
IL2R and ICOS signalling. Effector T cells are also characterised by high mTOR and metabolic activity, 
whereas FOXO1-dependent expression of lymph node homing receptors is reduced.  
Inhibition of PI3K signalling during thymic development is thought to favour the development of 
dƌĞŐ ?,ŽǁĞǀĞƌ ?W/ ?<ɷĂĐƚŝǀŝƚǇŝƐƌĞƋƵŝƌĞĚƚŽŵĂŝŶƚĂŝŶŶŽƌŵĂůŶƵŵďĞƌƐŽĨdƌĞŐĐĞůůƐŝŶƚŚĞƉĞƌŝƉŚĞƌĂů
lymphoid tissues and for Treg to adopt an effector phenotype, especially peripheral tissues.   
Maintainenance of low-level signaling (also referred to as tonic signalling) ǀŝĂW/ ?<ɷ ?ĂŶĚƚŽĂůĞƐƐĞƌ
ĞǆƚĞŶƚW/ ?<ɲ ?ŵĂŝŶƚĂŝŶƐƐƵƌǀŝǀĂůŽĨ naïve follicular B cells. Upon activation, PI3K is increased and this 
contributes to B cell proliferation. However, for B cells to undergo CSR in the GC, PI3<ɷƐŝŐŶĂůůŝŶŐ
needs to be tuned back down to allow higher FOXO1 transcription and proper AID targeting. 
In disease states (bottom) caused by gain-of-function or loss-of-function in PI3KG, the proper 
dynamics of signalling result in cellular defects associated with immunodeficiency. Chronically high 
PI3KG activity leads to T cell (more senescence, death, and Tregs) and B cell (more transitional B cells 
and less CSR and SHM) abnormalities with increased susceptibility to B cell lymphoma, infections, 
and lymphoproliferative disease.  Chronically low PI3KG activity leads to a different set of T cell (poor 
responses and low Tregs) and B cell (low numbers) abnormalities resulting in prevalent infections 
and colitis.   
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Figure 4. APDS mutations lower the threshold of PI3Kį activation  
a | Schematic diagram of the protein domains in the Ɖ ? ?ɲƌĞŐƵůĂƚŽƌǇĂŶĚƉ ? ? ?ɷĐĂƚĂůǇƚŝĐƐƵďƵŶŝƚƐ
with mapped interactions shown with lines, where the black line indicates the binding interaction 
mediated constitutive interaction and the red lines indicate inhibitory contacts.  The locations of the 
described amino acid substitutions caused by APDS mutations are indicated. ABD: adaptor-binding 
domain, RBD: RAS-binding domain, SH3: SRC-homology 3 domain, P: proline-rich region, BH: 
breakpoint-cluster region homology domain, SH2: SRC-homology 2 domain, N-: N-terminal, C-: C-
terminal, i-: inter-. 
b | Class IA PI3Ks are activated by their recruitment to tyrosine kinase-associated receptors at the 
ƉůĂƐŵĂŵĞŵďƌĂŶĞ ?dŚĞƉ ? ?ɲƌĞŐƵůĂƚŽƌǇƐƵďƵŶŝƚ ?Ɖ ? ?ĨƌĂŐŵĞŶƚĐŽŶƚĂŝŶŝŶŐƚŚĞN-SH2 Wi-SH2 WC-SH2 
domains, shown here in blue ?ƐƚĂďŝůŝǌĞƐƚŚĞƉ ? ? ?ɷĐĂƚĂůǇƚŝĐƐƵďƵŶŝƚ ?orange) through constitutive 
ďŝŶĚŝŶŐŽĨƚŚĞƉ ? ?ɲŝ-^, ?ĚŽŵĂŝŶ ?ĐŽŝůĞĚƉŽƌƚŝŽŶ ?ƚŽƚŚĞƉ ? ? ?ɷĂĚĂƉƚŽƌ-binding domain (ABD). 
ŝŶĚŝŶŐŽĨƚŚĞƉ ? ?ɲ^, ?ĚŽŵĂŝŶƐƚŽƚǇƌŽƐŝŶĞ-phosphorylated residues on an activated receptor 
releases the inhibitory contacts between the p8 ?ɲ^, ?ĚŽŵĂŝŶƐĂŶĚƚŚĞƉ ? ? ?ɷ ? ?ŚĞůŝĐĂůĂŶĚ
kinase domains (shown in red in part a) ?/ƚŝƐƉŽƐƐŝďůĞƚŚĂƚƚŚĞȴǆ ? ?ŵƵƚĂƚŝŽŶ ?red) that truncates 
ƚŚĞƉ ? ?ɲŝŶƚĞƌ-^, ?ĚŽŵĂŝŶĂĨĨĞĐƚƐƉ ? ? ?ɷŵŽƌĞƚŚĂŶŝƚĂĨĨĞĐƚƐƉ ? ? ?ɲ ?ŚĞŶĐĞƚŚĞůĂĐŬŽĨŵŽƌĞ
dramatic pleiotropic effects on growth and metabolism in individuals with this deletion. Ras WGTP 
ĨƵƌƚŚĞƌƚĞƚŚĞƌƐƉ ? ? ?ɷƚŽƚŚĞŵĞŵďƌĂŶĞďǇďŝŶĚŝŶŐƚŽƚŚĞZĂƐ-ďŝŶĚŝŶŐĚŽŵĂŝŶ ?Z ?ŽĨƉ ? ? ?ɷ ?'K&
mutations in PIK3R1 and PIK3CD increase kinase activity by interfering with inhibitory interactions 
ďĞƚǁĞĞŶƚŚĞƉ ? ?ɲƌĞŐƵůĂƚŽƌǇĂŶĚƉ ? ? ?ɷĐĂƚĂůǇƚŝĐƐƵďƵŶŝƚ ?ȴǆ ? ? ?E ? ? ?< ? ? ? ?Zand E525K), or by 
ŝŶĐƌĞĂƐŝŶŐƚŚĞĂĨĨŝŶŝƚǇŽĨƉ ? ? ?ɷĨŽƌƚŚĞƉůĂƐŵĂŵĞŵďƌĂŶĞ ? ? ? ? ?< ? ?dŚĞ ? ? ? ?<ŵƵƚĂƚŝŽŶƐŵĂǇĂůƐŽ
interfere with inhibitory contacts from the p85ɲ-SH2 domain1. See ref (17) and references therein 
ĨŽƌĨƵƌƚŚĞƌĚĞƚĂŝůƐŽĨƚŚĞƐƚƌƵĐƚƵƌĞƐĂŶĚŵĞĐŚĂŶŝƐŵƐŽĨƌĞŐƵůĂƚŝŽŶŽĨW/ ?<ɷ ?
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Glossary terms 
 
ĐƚŝǀĂƚĞĚW/ ?<ɷƐǇŶĚƌŽŵĞ 
(APDS) 
The term APDS encompases two syndromes: APDS1 (also known as PASLI-CD), which result from  a 
mutation in the PIK3CD gene that lead to the ŚǇƉĞƌĂĐƚŝǀĂƚŝŽŶŽĨƚŚĞƉ ? ? ?ɷƐƵďƵŶŝƚŽĨW/ ?<ɷ; 
and.APDS2 (also known as PASLI-R1), which results from splice mutations in PIK3R1 that lead to exon 
skipping and produces ĂƚƌƵŶĐĂƚĞĚƉ ? ?ɲƉƌŽƚĞŝŶǁŝƚŚƌĞĚƵĐĞĚŝŶŚŝďŝƚŝŽŶŽĨƉ ? ? ?ɷ  
  
Activation-induced cytidine deaminase (AID) 
An enzyme that is required for two crucial events in the germinal centre: somatic hypermutation and 
class-switch recombination. 
 
Germinal centre reaction 
Germinal centres are specialised structures within spleens and lymph nodes where B cells present 
antigen to T cells and in return, are selected to undergo CSR and SHM. 
 
Hypogammaglobulinemia 
 An immune disorder characterised by low serum IgG levels. 
  
Immune complexes 
Complexes of antigen bound to antibody and, sometimes, components of the complement system. 
The levels of immune complexes are increased in many autoimmune disorders, in which they 
become deposited in tissues and cause tissue damage. 
 
Class-switch recombination (CSR) 
The process by which proliferating B cells rearrange their DNA to switch from expressing IgM 
(or another class of immunoglobulin) to expressing a different immunoglobulin heavy-chain 
constant region, thereby producing antibody with different effector functions.  
 
T cell-independent (TI) antibody response  
An antibody response to polymeric antigens, such as polysaccharides and lipids, that does not 
require T cell help. 
 
Primary immunodeficiency (PID) 
An inherited disorder of the immune system that leads to recurrent infections and/or immune 
dysregulation. Currently there are around 84,000 patients diagnosed worldwide with PID. 
 
Somatic hypermutation (SHM) 
A unique mutation mechanism that is targeted to the variable regions of rearranged immunoglobulin 
gene segments. Combined with selection for B cells that produce high-affinity antibody, SHM leads 
to affinity maturation of B cells in germinal centres. 
 
T follicular helper cells (Tfh cells) 
CD4+ T helper cells that are essential for the induction of class switching in the germinal centres of 
secondary follicles during antibody responses to T cell-dependent antigens. 
 
Transitional B cells 
Immature B cells that have left the bone marrow for the spleen and are precursors of follicular B 
cells, marginal zone B cells and B1 B cells. 
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Senescence 
A state in which a cell fails to progress through the cell cycle due to activation of the DNA damage 
response, which can occur upon extreme shortening of telomeres. 
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at doses tested in leukaemia/lymphoma trials, possibly due to effects on Treg. 
 
x ĐƚŝǀĂƚĞĚW/ ?<ɷ^ǇŶĚƌŽŵĞ ?W^ ?ŝƐĂŶĞǁůǇĚĞƐĐƌŝďĞĚƉƌŝŵĂƌǇŝŵŵƵŶŽĚĞĨŝĐŝĞŶĐǇĐĂƵƐĞĚďǇ
hyperactive PI3K  signalling and resultant T cell senescence/death and impaired antibody 
responses.  APDS is generally characterized by recurrent sinopulmonary infections with 
structural lung damage, viremia with herpes family viruses, lymphoproliferative disease, and 
increased risk of B cell malignancies. 
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x APDS1 patients have a heterozygous ŵƵƚĂƚŝŽŶŝŶW/< ? ?ƚŚĞŐĞŶĞĞŶĐŽĚŝŶŐƚŚĞƉ ? ? ?ɷ
catalytic subunit of W/ ?<ɷ ?ǁŚĞƌĞĂƐW^ ?ƉĂƚŝĞŶƚƐŚĂǀĞĂheterozygous mutation in PIK3R1, 
ƚŚĞŐĞŶĞĞŶĐŽĚŝŶŐƚŚĞƉ ? ?ɲƌĞŐƵůĂƚŽƌǇƐƵďƵŶŝƚŽĨW/ ?<ɷ ?Both sets of mutations lead to 
ŚŝŐŚĞƌŝŶƚƌŝŶƐŝĐĂĐƚŝǀŝƚǇŽĨW/ ?<ɷ ?
 
x To date, most APDS patients have been treated with antibody replacement therapies and 
some with the mTOR inhibitor rapamycin. In the future, W/ ?<ɷŝŶŚŝďŝƚŽƌƐŵĂǇďĞƵƐĞĚƚŽ
treat APDS patients, possibly as the first example of targeted therapy against a hyperactive 
mutant kinase in primary immunodeficiency. 
